<DOC>
	<DOCNO>NCT03005210</DOCNO>
	<brief_summary>Comparative randomize , single dose , three way three sequence two treatment partial replicate crossover open-label study determine bioequivalence Sofosbuvir Ledipasvir Magicbuvir Plus 90/400 mg Tablets ( Magic Pharma , Egypt ) Versus Harvoni 90/400 mg Tablets ( Gilead Sciences , Canada ) Healthy Human Volunteers Under Fed Condition .</brief_summary>
	<brief_title>A Study Sofosbuvir Ledipasvir From Magicbuvir Plus 90/400 mg Tablets ( Magic Pharma , Egypt ) Versus Harvoni 90/400 mg Tablets ( Gilead Sciences , USA )</brief_title>
	<detailed_description>Primary Pharmacokinetic Parameters : Cmax , Area cover ( AUC0→t AUC0→∞ ) Secondary Pharmacokinetic Parameters : Ke , tmax t1/2e . ANOVA use 5 % significance level transform ( 90 % confidence interval ) untransformed data Cmax , AUC0→t AUC0→∞ untransformed data Ke , tmax t1/2e . The confidence interval logarithmically transform Test/Reference ratio Cmax , AUC0→t AUC0→∞ within 80.00-125.00 % . A comprehensive final report issue upon completion study .</detailed_description>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>1 . Healthy male female , age 18 55 year , inclusive . 2 . Body weight within 15 % normal range accord accept normal value body mass index ( BMI ) . 3 . Medical demographic without evidence clinically significant deviation normal medical condition . 4 . Results clinical laboratory test within normal range deviation consider clinically significant principal investigator . 5 . Subject allergy drug investigation . 1 . Subjects know allergy product test . 2 . Subjects whose value BMI outside accept normal range . 3 . Female subject pregnant , nurse take birth control pill . 4 . Medical demographic evidence clinically significant deviation normal medical condition . 5 . Results laboratory test clinically significant . 6 . Acute infection within one week precede first study drug administration . 7 . History drug alcohol abuse . 8 . Subject agree take prescription nonprescription drug within two week first study drug administration end study . 9 . Subject special diet ( example subject vegetarian ) . 10 . Subject agree consume beverage foods contain methylxanthenes e.g . caffeine ( coffee , tea , cola , chocolate etc . ) 48 hour prior study administration either study period donate last sample respective period . 11 . Subject agree consume beverage foods contain grapefruit 7 day prior first study drug administration end study . 12 . Subject history severe disease direct impact study . 13 . Participation bioequivalence study clinical study within last 6 week first study drug administration . 14 . Subject intend hospitalize within 3 month first study drug administration . 15 . Subjects , completion study , would donate 500 ml blood 7 day , 750 ml blood 30 day , 1000 ml 90 day , 1250 ml 120 day , 1500 ml 180 day , 2000 ml 270 day , 2500 ml blood 1 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>